RM LAW, P.C. has commenced an investigation into potential securities law violations by certain officers of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).
If you purchased shares of MiMedx and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.
On February 20, 2018, before the market opened, MiMedx issued a press release disclosing the delay in the release of its fourth quarter 2017 financial results as its Audit Committee is conducting “an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company.” MiMedx is “also reviewing, among other items, the accounting treatment of certain distributor contracts.”
As a result of the disclosure, MiMedx stock price declined more than $4.50 per share on intraday trading on February 20, 2018.